8BA4F4D7-5FCD-42B8-B000-108067FE6885
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 23.45597897503285
- age_years
- 24
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.537
- INTERFERON_ALPHA_RESPONSE+0.447
- TGF_BETA_SIGNALING+0.395
- MYC_TARGETS_V1+0.381
- IL6_JAK_STAT3_SIGNALING+0.355
- PROTEIN_SECRETION+0.354
- INTERFERON_GAMMA_RESPONSE+0.350
- MITOTIC_SPINDLE+0.346
- E2F_TARGETS+0.307
- WNT_BETA_CATENIN_SIGNALING+0.307
Top 10 suppressed
- KRAS_SIGNALING_DN-0.331
- SPERMATOGENESIS-0.290
- MYOGENESIS-0.208
- PANCREAS_BETA_CELLS-0.196
- APICAL_SURFACE-0.156
- ESTROGEN_RESPONSE_LATE-0.116
- COAGULATION-0.114
- BILE_ACID_METABOLISM-0.032
- UV_RESPONSE_UP-0.026
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.936 |
| 2 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.924 |
| 3 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.923 |
| 4 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.915 |
| 5 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.914 |
| 6 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.912 |
| 7 | 4880B586-BA92-48B2-A233-5C245D2E31C0 | — | — | 0.906 |
| 8 | EFB459E3-9B6A-4020-8556-6409065823B7 | — | — | 0.905 |
| 9 | C969CDC5-D2DC-4F7B-B84B-C53CEF26B2CF | — | — | 0.901 |
| 10 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.537 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.447 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.395 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.381 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.355 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.354 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.346 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.307 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.307 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.302 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.288 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.285 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.246 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.233 | Inavolisib | — uncovered |
| APOPTOSIS | 0.231 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.219 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.203 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.174 | Inavolisib | — uncovered |